Characterization of a low mutation rate E. coli in extended fermentation
Characterization of a low mutation rate E. coli in extended fermentation
批准号:
9276026
负责人:
FREDERICK R BLATTNER
金额:
$86.41万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-05-01 至 2019-05-31
关键词:
AddressAdoptedAdoptionAntibodiesAntitoxinsAttenuatedBiologicalBiological ContainmentBiological ProductsCytoplasmic ProteinDNA Transposable ElementsDNA analysisDNA sequencingDataDiphtheria ToxinDoseDrug IndustryEngineeringEquipmentEscherichia coliExperimental DesignsFailureFermentationFundingGelsolinGene ProteinsGenesGeneticGenetic EngineeringGenomeGenome engineeringGenomicsGoalsIS ElementsIndustrializationMedicineMembrane ProteinsMethodsMicrobial BiofilmsModelingModificationMonitorMutationOrganismPatientsPeptide HydrolasesPerformancePharmaceutical PreparationsPharmacologic SubstancePhaseProblem SolvingProceduresProcessProductionProphagesProteinsPumpReactionReadinessRunningSeedsSignal TransductionStressSystemTechnologyTestingTherapeuticTimeToxinToxoidsVaccinesWorkbasec newcommercializationcostcross reacting material 197designexperimental studyflasksfootgenome sequencingimprovedinstrumentationnucleaseplasmid DNAproductivity lossprogramsprototypepublic health relevancerepairedsensorsoftware development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Scarab Genomics was founded to improve E coli as an industrial organism by genome engineering. These strains have stable genomes since all prophages, transposable and IS elements, and the error prone repair systems were removed. A recA- version has always been provided as an option. The goal of the Phase I project was to ascertain whether the changes already introduced are sufficient to realize extended or continuous fermentation. Data gathered in Phase I show that we have indeed supported that hypothesis. Data obtained using serial transfer with shake flasks met our criterion for production stability of 21 days, but only when the cultures were not induced. This suggested the use of a two tank system with seed and production tanks. To confirm this we performed actual fermentations using Scarab funds. The results show that stable production of a test protein, CRM197 can be extended at least 33 days with no loss of productivity. This is more than enough to justify a 10 fold lowering of the cost of production with continuous flow rather than fed
batch procedures that have been used in for manufacturing in E. coli. Continuous cultures were also analyzed by DNA sequencing and this was able to detect contamination as well as mutations and rearrangements. This analysis also revealed that the Scarab strain competed well against contaminants in contrast to standard strains BL21. We are therefore proposing to take this system to the next level by developing a complete platform for continuous fermentation, called C-Flow. The FDA has recently encouraged adoption of continuous manufacturing in the pharmaceutical industry, and several large companies have recently signaled readiness to implement the change. Our aim is to attack the bottom line of E. coli fermentation by offering a simpler and cheaper process that will produce consistently higher quality bioproducts than fed batch fermentation. Our proposal is to fully characterize the C-flow system and work towards commercializing it by developing a prototype that fits in a standard 6 ft hood. One particularly useful feature will support optimization of fermentation parameters without the need to restart fermentation so the best possible performance can be quickly and inexpensively achieved by a user. Other products such as pDNA will be tested in the C-Flow system.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Software for the complete characterization of antibody repertoires: from germline and mRNA sequence assembly to deep learning predictions of their protein structures and targets
-
批准号:10699546
-
项目类别:
-
资助金额:$64.88万
-
财政年份:2023
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture
-
批准号:10081714
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2020
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
-
批准号:10603473
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2020
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture
-
批准号:10215525
-
项目类别:
-
资助金额:$94.45万
-
财政年份:2020
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening
-
批准号:10385733
-
项目类别:
-
资助金额:$99.87万
-
财政年份:2020
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli
-
批准号:9926039
-
项目类别:
-
资助金额:$91.12万
-
财政年份:2019
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Characterization of a low mutation rate E. coli in extended fermentation
-
批准号:8455785
-
项目类别:
-
资助金额:$28.26万
-
财政年份:2013
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
-
批准号:8252834
-
项目类别:
-
资助金额:$14.09万
-
财政年份:2012
-
负责人:FREDERICK R BLATTNER
-
依托单位:
A protease-deficient, low mutation rate E. coli for biotherapeutics production
-
批准号:8727638
-
项目类别:
-
资助金额:$71.35万
-
财政年份:2012
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
-
批准号:9897524
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2012
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
-
批准号:8782091
-
项目类别:
-
资助金额:$73.3万
-
财政年份:2012
-
负责人:FREDERICK R BLATTNER
-
依托单位:
A protease-deficient, low mutation rate E. coli for biotherapeutics production
-
批准号:8455486
-
项目类别:
-
资助金额:$13.68万
-
财政年份:2012
-
负责人:FREDERICK R BLATTNER
-
依托单位:
A protease-deficient, low mutation rate E. coli for biotherapeutics production
-
批准号:8581663
-
项目类别:
-
资助金额:$91.1万
-
财政年份:2012
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Uniform length DNA for paired end nextgen sequencing via in vitro packaging
-
批准号:8001230
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2010
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Innate Immune Protection by Clean Genome E. coli
-
批准号:7911224
-
项目类别:
-
资助金额:$14.0万
-
财政年份:2010
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Innate Immune Protection by Clean Genome E. coli
-
批准号:8202257
-
项目类别:
-
资助金额:$99.6万
-
财政年份:2010
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Innate Immune Protection by Clean Genome E. coli
-
批准号:8228097
-
项目类别:
-
资助金额:$73.75万
-
财政年份:2010
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Engineered revision of the E. coli Nissle 1917 Genome
-
批准号:7481836
-
项目类别:
-
资助金额:$14.1万
-
财政年份:2008
-
负责人:FREDERICK R BLATTNER
-
依托单位:
15th Annual International Conference on Microbial Genomics
-
批准号:7407963
-
项目类别:
-
资助金额:$1.9万
-
财政年份:2007
-
负责人:FREDERICK R BLATTNER
-
依托单位:
Improved bacterial strains for therapeutic DNA production
-
批准号:7271734
-
项目类别:
-
资助金额:$13.92万
-
财政年份:2007
-
负责人:FREDERICK R BLATTNER
-
依托单位:
海外基金